13F Holdings
中文EN

TARS Tarsus Pharmaceuticals, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1819790 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY86.3%
TTM net income YoY-765.3%
TTM EPS YoY-697.0%
Revenue 3-yr CAGR262.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-102.0%
Net margin-102.9%
FCF margin4.8%
EBITDA margin-101.7%

Returns

ROE-319.8%
ROA-135.0%
ROIC (approx.)-330.8%
Asset turnover1.31x

Leverage & solvency

Liabilities / assets79.4%
Debt / equity0.70x
Current ratio1.96x
Interest coverage-80.17x

Cash quality & payout

Operating cash flow / net income-0.07x
Accruals ratio-144.6%
Payout ratio—
Capex / revenue2.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$451.36M$182.95M$17.45M$25.82M$57.03M
R&D expense$64.32M$53.39M$50.31M$42.62M$41.71M
SG&A expense$427.32M$237.31M$108.70M$44.95M$25.40M
Operating income-$70.97M-$120.57M-$143.16M-$62.71M-$12.16M
Interest expense$8.94M$7.85M$3.35M$2.20M$0
Pretax income-$64.36M-$115.55M-$135.89M-$62.09M-$13.77M
Income tax$2.06M$0$0-$4,000$55,000
Net income-$66.42M-$115.55M-$135.89M-$62.09M-$13.83M
EBITDA-$70.11M-$119.88M-$142.41M-$62.39M-$11.86M
EPS (basic)-1.59-3.07-4.62-2.52-0.67
EPS (diluted)-1.59-3.07-4.62-2.52-0.67
Dividends declared per share0.000.000.000.000.00
Weighted avg. shares (diluted)41.78M37.60M29.38M24.62M20.55M
Balance sheet
Cash & equivalents$183.64M$97.38M$224.95M$71.66M$171.33M
Short-term investments$233.63M$196.56M$2.50M$145.37M$483,000
Receivables$85.06M$46.76M$16.62M$0$0
Inventory$4.37M$2.62M$3.11M$0—
Current assets$522.78M$356.70M$256.13M$225.38M$175.95M
PP&E, net$11.66M$2.31M$1.47M$957,000$755,000
Intangibles$7.37M$8.33M$3.87M$0—
Total assets$562.16M$376.99M$265.49M$227.86M$178.91M
Current liabilities$135.69M$80.61M$36.94M$15.43M$11.48M
Long-term debt$72.44M$71.84M$29.82M$19.43M$0
Total debt$72.44M$71.84M$29.82M$19.43M$0
Total liabilities$218.73M$152.46M$68.50M$34.96M$12.18M
Shareholders' equity$343.43M$224.53M$196.99M$192.90M$166.73M
Net debt-$111.20M-$25.54M-$195.13M-$52.23M-$171.33M
Shares outstanding42.55M38.35M34.21M26.70M20.70M
Cash flow statement
Operating cash flow-$12.45M-$83.03M-$117.49M-$49.03M$3.75M
Capital expenditure$9.86M$1.57M$1.50M$506,000$586,000
Free cash flow-$22.31M-$84.59M-$119.00M-$49.54M$3.16M
Investing cash flow-$42.12M-$199.19M$140.60M-$144.63M-$586,000
Financing cash flow$143.39M$154.66M$130.18M$93.99M$21,000
Depreciation & amortization$855,000$685,000$744,000$326,000$300,000
Stock-based compensation$41.72M$27.82M$19.83M$13.46M$8.46M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.